 |
|
|
| |
How should scale up of HCV antiviral treatment be prioritized?
A cost-effectiveness analysis including individual and population prevention benefits
|
| |
| |
Reported by jules Levin
EASL April 22-26 2015 Vienna Austria
Natasha Martin1,2, Peter Vickerman1, Gregory Dore3, Jason Grebely3, Alec Miners4, John Cairns4, Graham Foster5, Sharon Hutchinson6,7, David Goldberg7, Thomas Martin8, Mary Ramsay9, Matthew Hickman1
1School of Social and Community Medicine, University of Bristol 2Division of Global Public Health, University of California San Diego 3Kirby Institute, UNSW Australia, Sydney 4Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine. 5Queen Mary's University of London 6Glasgow Caledonian University 7Health Protection Scotland 8Guy's and St Thomas's 9Public Health England
|
| |
|
|
|
|
|
